Back to the leaderboard
@pcm_bio · Exit NVO
Read asExit NVO
Since the call—
unrankedThe analyst's rank today
High · 0.93Confidence
Fri, Oct 16Tweeted
Mon, Oct 19 closeCounted from
not in the basket todayBasket
Rank per close
—Oct 19
Patients Capital Management LLC@PCM_bio$NVO The effects of high product concentration with (stronger) competition from $lly .. shifting risk from commercial execution to pipeline, which hasn't proven differentiated. Need additional legs on commercial stool to turn trend on equity beta -> reduce WACC -> create opp for
Patients Capital Management LLC@PCM_bio1st Pharma in the "must-transact" basket: $nvo 5-Year (Inf. Adj) CAGR: 1.02% Revenue Gap to 5% CAGR: $11bn Top product concentration: ~75% Net debt-to-EBITDA: 0.7x Capacity: target dependent / not meaningful metric
